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Introduction 68
The four serotypes of dengue virus (DENV-1 to -4) are the most important causes of 69 the rapidly emerging arthropod-borne disease in tropical and subtropical countries [1, 2] , 70
where an estimated 390 million dengue cases occur annually [3] . Infection with one serotype 71 provides long-term homotypic protective immunity, while heterotypic protection is short-72 lived. Therefore, a tetravalent vaccine is necessary for a balanced immunity against all four 73 DENV serotypes [4] . The most advanced dengue vaccine is the live-attenuated chimeric 74 yellow fever virus-DENV tetravalent dengue vaccine (CYD-TDV) that expresses the 75 premembrane (prM) and envelope (E) structural protein genes of each of the four DENV 76 serotypes [5] . Even though pooled data from phase III clinical trials showed that CYD-TDV 77 had lower efficacy against DENV-1 and -2 [6-8], it has been licensed in some countries under 78 the condition of limited use for individuals aging 9 to 45 years old. A next-generation dengue 79 vaccine with higher efficacy is urgently needed for use in a population of wider age group. 80
Other candidates are in development including purified inactivated virus, subunit and DNA 81 vaccines [9] . 82 DNA vaccines afford advantages over the other vaccine platforms including ease and 83 safety of production, elimination of replication interference [10] , stimulation of CD8 + and 84 CD4 + T cell responses similar to live-attenuated vaccines [11] , and the possibility to 85 formulate vaccines against multiple pathogens in a single vaccination. However, DNA 86 vaccines elicit low neutralizing antibodies than protein-based vaccines due to unsatisfactory 87 uptake by host cells and inadequate antigen expression. This was overcome by heterologous 88 prime-boost immunizations, with combined use of DNA and other vaccine formats, which 89 effectively induce a more robust and durable immune response against a number of medically 90 important viruses including HIV [12] , influenza [13, 14] , HCV [15] , and flaviviruses [16] [17] [18] [19] [20] [21] [22] . 91 DENV infection elicits a poor quality of immune response that is highly skewed in the 92 production of immunodominant antibodies against cross-reactive poorly neutralizing epitopes 93 in E protein ectodomain II fusion peptide (EDII FP ) [23, 24] . These EDII FP antibodies can 94 induce a severe disease resembling dengue hemorrhagic fever as demonstrated in AG129 95 mice via antibody-dependent enhancement (ADE) of infection [25] [26] [27] . Previously our group 96 have constructed a DENV-2 wild-type (DENV-2 WT) plasmid containing the prM and E 97 structural protein genes, which can be secreted outside of the transfected cells and forms 98 virus-like particle (VLP) [28, 29] . The DENV-2 WT plasmid is also demonstrably 99 immunogenic and protective in immunized mice when administered as DNA or VLP [28] [29] [30] . 100
To circumvent the potential for a severe form of DENV-associated disease after infection by vaccine-induced EDII FP antibodies through ADE, our group further engineered a cross-102 reactivity reduced (CRR) DENV-2 DNA vaccines with substitutions in the EDII FP epitopes 103 [24, 31] . These CRR DNA vaccines not only induced a significantly reduced levels of EDII FP 104 antibodies, which consequently reduced the enhancement of DENV infection in vitro and in 105 vivo, but also sculpted the immune response towards an increased level of DENV complex- 
DENV-2 WT vaccine prime-boost immunizations elicit DENV-specific antibodies 168
To test if different prime-boost strategies using DNA or VLP would improve the 169 immunogenicity of DENV-2 WT vaccine, ICR mice were immunized with combinations of 170 DNA and VLP vaccines. All prime-boost strategies induced DENV-specific IgG titers 171 ranging from 2.5 × 10 2 to 3.7 × 10 5 ( Fig. 1A-D) . The IgG mean titer against the homologous 172 DENV-2 ( Fig. 1A, Supplemental Table 1 ) was significantly higher with WT VLP-VLP (1.9 173 × 10 5 ; p=0.0172) than WT DNA-DNA (2.3 × 10 4 ). The titers induced by WT DNA-VLP or 174 WT VLP-DNA were also slightly higher (8.3 × 10 4 and 7.1 × 10 4 , respectively) than WT 175 DNA-DNA without statistical significance. All prime-boost strategies induced IgG cross-176 reactive to heterologous DENV-1, -3 and -4. Again, WT DNA-DNA induced the lowest IgG 177 titer against DENV-1 (Fig. 1B) . Only WT VLP-DNA induced a significantly higher DENV-1 178 cross-reactive IgG mean titer (6.5 × 10 4 ; p=0.0451) than WT DNA-DNA (1.3 × 10 4 ), but not 179 compared to WT VLP-VLP and WT DNA-VLP (1.8 × 10 4 and 1.9 × 10 4 , respectively) 180 (Supplemental Table 1 ). No significant differences were observed in DENV-3 ( Fig. 1C) and 181 DENV-4 ( Fig. 1D) cross-reactive IgG titers. 182
All prime-boost strategies induced DENV-specific NtAb titers ranging from 10 to 1.3 183 × 10 3 (Fig. 1E-H) . Consistent with the total IgG results, WT VLP-VLP induced the highest 184
NtAb titer to homologous DENV-2 (7.7 × 10 2 ; Fig. 1E, Supplemental Table 1 ), although 185 only significantly higher than WT VLP-DNA (1.2 × 10 2 ; p=0.0169). Likewise, all prime-186 boost strategies induced antibodies with comparable cross-neutralizing activities against the 187 heterologous DENV-1, -3 and -4 ( Fig. 1F-H) . vaccines induced a significantly reduced proportions (means of 1%-6%) of IgG targeting the 202 WT EDII FP epitopes than the larger proportions (means of 32%-52%) induced by WT 203 vaccines (Fig. 2, Supplemental Table 1 ). Comparably, WT-RD and RD-WT vaccine 204 combinations also induced reduced WT EDII FP IgG (means of 1%-18% and 1-28%, 205 respectively) ( Fig. 2, Supplemental Table 1 ). 206 Next, we examined if different prime-boost strategies using DENV-2 RD vaccine can 207 sculpt the immune response towards CR NtAbs as previously described [32] by comparing 208 the immunogenicity against homologous and heterologous antigens. RD DNA-VLP induced 209 consistently higher DENV-specific IgG titers to all four DENV serotypes (Fig. 3A-D) . The 210
IgG mean titer against the homologous DENV-2 ( Fig. 3A, Supplemental Table 1 ) was 211 significantly higher with RD DNA-VLP (4.9 × 10 5 ) than RD VLP-VLP (3.7 × 10 4 ; p=0.0072) 212 and RD VLP-DNA (6.0 × 10 4 ; p=0.0201), but not compared to RD DNA-DNA (6.6 × 10 4 ). 213
Consistently, the NtAb mean titer against the homologous DENV-2 was significantly higher 214 with RD DNA-VLP (5.2 × 10 2 ; Fig. 3E, Supplemental Table 1 ) than RD VLP-DNA (7.3 × 215 10 1 ; p=0.0171) and RD DNA-DNA (3.2 × 10 1 ; p=0.0125), but not compared to RD VLP-216 VLP (3.2 × 10 2 ). 217
We further examined if prime-boost strategies using different forms of DENV-2 RD 218 antigens would broaden the immune response to heterologous DENV serotypes by re-219 directing the immune response from the immunodominant EDII FP site to DENV complex 220 epitopes. Comparable DENV-1 and -4 ( Fig. 3B and D) cross-reactive IgG titers were also 221 induced, but a significantly higher DENV-3 cross-reactive IgG mean titer induced by RD 222 DNA-VLP (2.3 × 10 4 ; p=0.0023; Fig. 3C, Supplemental Table 1 ) than RD VLP-DNA (1.9 223 × 10 3 ) was observed. On the contrary, the CR NtAb responses are serotype-dependent. A 224 significantly higher DENV-1 CR NtAb mean titer was elicited by RD VLP-VLP (3.4 × 10 2 ; 225 p=0.0053; Fig. 3F, Supplemental Table 1 ) than RD VLP-DNA (2.3 × 10 1 ). RD DNA-VLP 226 elicited comparably higher CR NtAb mean titer against DENV-3 (1.8 × 10 2 ; Fig. 3G,  227 Supplemental Table 1 ). The CR NtAb mean titers to DENV-4 are equivalently low for all 228 prime-boost strategies (<3.0 × 10 1 ; Fig. 3H, Supplemental Table 1) . 229
230

CRR DENV-2 RD vaccine only protects against homologous DENV-2 infection 231
Next, we assessed if the CR NtAbs induced by different prime-boost immunizations 232 of RD antigens can provide protection against lethal challenge of heterologous DENV 233 serotypes. The lack of an ideal animal model to evaluate protective efficacy of a vaccine 234 against the four DENV serotypes is one of the major hindrance in dengue vaccine 235 development. Even though interferon α/β/γ receptor-deficient (AG129) mouse has been used 236
in several studies for flavivirus vaccine evaluation [37-41], the challenge viruses for four 237 serotypes of DENV were not available at the time when we started this study. We instead 238 evaluated the efficacy of DENV-2 RD vaccine in lethally challenged suckling mice through 239 passive protection by transferred maternal antibodies from immunized female mice as 240 previously developed [28] [29] [30] . Utilizing suckling mouse model for evaluating vaccine 241 efficacy allows us to evaluate the protection from dengue virus challenge only comes from 242 maternal antibodies generated by vaccinated female mice and passively transferred to their 243 babies. Pups from RD DNA-VLP, RD DNA-DNA, RD VLP-VLP, and RD VLP-DNA 244 immunized mothers had 100%, 94%, 88%, and 83% protection, respectively, from 245 homologous DENV-2 infection (Fig. 4A) . However, no protection was observed after 246 heterologous DENV-1, -3 and -4 infections (Fig. 4B-D) , except for the pups from RD DNA-247 VLP immunized mother having 60% partial protection from DENV-3 challenge. Fig. 5) . In addition, the elicited sera showed varying IgG avidities (Supplemental Table 2 ). 258 RD DNA-VLP induced IgG with the highest avidity to the homologous DENV-2 followed by 259 VLP-VLP, DNA-DNA, and VLP-DNA (51%, 50%, 33%, and 18% respectively). No 260 avidities to DENV-1 and -3 were observed. Avidity to DENV-4 were also absent in sera 261 elicited by RD VLP-VLP and VLP-DNA. However, RD DNA-DNA and DNA-VLP sera had 262 minimal avidity to DENV-4 (21% and 3%, respectively) (Supplemental Table 1 ) yet had a 263 very poor CR NtAb mean titers (<2.0 × 10 1 ; Fig. 3H) . 264 265 266
Discussion
In this study, we extended our approach of dampening the immunodominance of 268 potentially pathogenic EDII FP epitopes by evaluating whether various prime-boost strategies 269 using the DENV-2 RD vaccine can further broaden the CR NtAb response. Results 270 demonstrate that heterologous RD DNA-VLP immunization can induce significantly higher 271 levels of NtAbs to homologous DENV-2 serotype comparable to the homologous RD VLP-272 VLP immunization. This could be attributed to the efficient boosting capability of protein 273 [19, [42] [43] [44] , which is readily available for antigen presentation during immunization as 274 opposed to the low-level expression of the immunogenic protein in response to DNA 275 immunization. Moreover, RD VLP-VLP and DNA-VLP immunizations were able to induce 276 an increase in DENV-1 and/or -3 CR NtAbs. 277
NtAbs has been considered to play a critical role in protection against DENV 278 infection. Therefore, we also evaluated the antibody-mediated cross-protection elicited by 279 DENV-2 RD vaccine through passive transfer of maternal antibodies. Interestingly, we 280 detected CR NtAbs in vitro but it did not predict in vivo cross-protection. We observed that 281 DENV-2 RD vaccine regardless of the prime-boost strategies is highly protective against 282 homologous DENV-2 infection; however, it does not confer cross-protection against the 283 heterologous serotypes. The elicited CR NtAbs evidently did not provide cross-neutralizing 284 protection against the other DENV serotypes, which could be partly due to the amount of the 285 elicited CR NtAbs and/or IgG avidities [45, 46] . As reports suggested, high antibody avidities 286 correlate to better protection after vaccination [47, 48] . Indeed, the sera elicited from DENV-287 2 RD immunizations have avidities and high neutralization towards the homologous DENV-2 288 but not to the heterologous DENV-1 and -3. The absence of cross-protection against DENV-4 289 could be due to the suboptimal levels of DENV-4 CR NtAbs and/or the absence of avidities. 290
In summary, our study confirms the poor correlate of neutralization titers with the protection 291 from four serotypes of DENV infection as suggested by the results of CYD-TDV clinical 292 trials [49, 50] . 293
Overall, this study underscores the need for a multivalent formulation of our CRR 294 DENV vaccines to fully harness its potential benefits with reduced ADE risk for dengue 295 vaccine safety and broaden its protective efficacy. Importantly, the strategy of a heterologous 296 DNA priming and VLP boosting highlights an effective platform of eliciting a better quality 297 of immune response to DENV. 
